Drug Landscape ›
IV Iron ›
Regulatory · United States
Marketing authorisations
FDA — authorised 6 November 2000
Application: NDA021135
Marketing authorisation holder: AM REGENT
Local brand name: VENOFER
Indication: INJECTABLE — INTRAVENOUS
Status: approved
Read official source →
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 13
Most-reported reactions
Blood Creatinine Increased — 2 reports (15.38%) Drug Hypersensitivity — 2 reports (15.38%) Drug Ineffective — 2 reports (15.38%) Abdominal Pain — 1 report (7.69%) Aphasia — 1 report (7.69%) Arthralgia — 1 report (7.69%) Blood Calcium Decreased — 1 report (7.69%) Blood Glucose Decreased — 1 report (7.69%) Cerebrovascular Accident — 1 report (7.69%) Chest Pain — 1 report (7.69%)
Source database →
IV Iron in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is IV Iron approved in United States?
Yes. FDA authorised it on 6 November 2000; FDA has authorised it.
Who is the marketing authorisation holder for IV Iron in United States?
AM REGENT holds the US marketing authorisation.